CD19 and systemic lupus erythematosus: Additionally, since the efficacy of anti-CD19 conventional CAR-T cells has been recently reported in refractory SLE in patients23,24, in this model we also tested the effect of 19CAR-Tconvs (3.5 M of cells/mouse), injected 3 weeks after pristane administration (early therapeutic regimen, Fig. 7a and Suppl.